Skip to contentS
Sarepta Therapeutics, Inc.
S
SRPTSarepta Therapeutics, Inc. Q2 2018 · 10-Q
Revenue$73.53M$73.53M+110.0% vs Q2 2017 Net Income-$109.27M-$109.27MN/M vs Q2 2017 EPS Diluted-$1.67-$1.67N/M vs Q2 2017 Operating Income-$103,427,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Sarepta Therapeutics, Inc. · CIK 873303 · Engraved from SEC EDGAR
derived
Free Cash Flowderived-$125,951,000N/M Margins · derivedOperating margin-140.7%+40.3 pt vs Q2 2017
Net margin-148.6%+31.5 pt vs Q2 2017
ended Jun 30, 2018 · filed Aug 8, 2018 · 39 d after period end